ClinicalTrials.gg
RecruitingNCT07482995Updated Nov 5, 2026

Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults

An interventional study of Baduanjin exercise and General Health Education in Sedentary Lifestyle and Behavioral Intervention, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Sedentary Behavior with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Sedentary Behavior · China.

Planned enrollment
3rd of 23
208 · median 75
Started
2026
with 8 others
No phase
23 of 23
10 open now
Primary completion
2027-09
later than 8 of 10 live
Registered
13th of 23
by date
Lead sponsor
1 of 23
China-Japan Friendship Hospital

Among the 23 studies in Sedentary Behavior with a site in China, this one is the 3rd largest by planned enrollment, is one of 9 that started in 2026, is one of 23 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 13th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

10 of the 23 studies in Sedentary Behavior with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Sedentary Behavior with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a 12-week Baduanjin exercise program can improve health in sedentary young and middle-aged adults. The main questions it aims to answer are:

  1. Does the Baduanjin program improve participants' cardiorespiratory fitness (measured as peak oxygen uptake)?
  2. Does it improve their body composition, muscle strength, balance, and flexibility?
  3. Does it reduce their daily sitting time?

Researchers will compare the Baduanjin training group to a health education control group to see if Baduanjin is more effective in improving these health outcomes.

Participants will:

  1. Be randomly assigned to one of the two groups.
  2. If in the Baduanjin group, attend supervised group sessions and practice at home for 12 weeks.
  3. Complete a series of assessments at the beginning, middle, and end of the study, including fitness tests, body measurements, and questionnaires.
03

Conditions studied

  • Sedentary Lifestyle
  • Behavioral Intervention

Browse trials for

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 59 years
  • Sedentary and physically inactive, defined as: (a) self-reported sitting time ≥ 8 hours per day, AND (b) not meeting the World Health Organization (WHO) recommended level of physical activity ( engaging in \< 150 minutes of moderate-to-vigorous intensity physical activity per week, assessed by the International Physical Activity Questionnaire [IPAQ])
  • In good general health as self-reported, and free from any known diseases
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • to cardiopulmonary exercise testing
  • Currently participating in, or planning to participate within the next 3 months, in any other structured exercise or behavioral intervention program
  • Pregnancy, lactation, or planning to become pregnant during the study period
  • Inability to understand or comply with the study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Baduanjin Training Group

    Participants in this group will receive a 12-week Baduanjin exercise program. The program consists of supervised group sessions combined with home-based practice, with a frequency of 5 sessions per week. Each session lasts 60 minutes, including warm-up, standardized Baduanjin practice, and cool-down. The Baduanjin exercises follow a standardized protocol.

    Behavioral: Baduanjin exercise

  • Other
    Health Education Control Group

    Participants in this group will receive general health education, which includes recommendations on physical activity types and duration (e.g., following the WHO guidelines). However, they will not be enrolled in any structured, supervised exercise program. They will be instructed to maintain their usual lifestyle throughout the study period.

    Other: General Health Education

Interventions

  • BehavioralBaduanjin exercise

    A 12-week, standardized Baduanjin exercise program. Participants will complete 5 sessions per week, each lasting 60 minutes (including warm-up, Baduanjin practice, and cool-down). The program includes both supervised group sessions and guided home practice.

  • OtherGeneral Health Education

    Participants will receive general health education (including recommendations on physical activity types and duration), but will not be enrolled in any structured or supervised exercise program. They will be instructed to maintain their usual lifestyle.

06

What researchers measure

Primary outcomes

  1. Change in Peak Oxygen Uptake (VO₂peak) assessed by Cardiopulmonary Exercise Testing

    Measured by Cardiopulmonary Exercise Testing (CPET).

    Time frame: at baseline and Week 13.

Secondary outcomes

  1. Change in Sit-and-Reach Distance

    Assessed by the standard sit-and-reach test.

    Time frame: at baseline, Week 8, and Week 13.

  2. Change in Active Range of Motion of the Shoulder, Hip, Knee, and Ankle joints assessed by Goniometry

    Measured using a goniometer

    Time frame: at baseline, Week 8, and Week 13.

  3. Change in Time Spent in Sedentary Behavior assessed by the International Physical Activity Questionnaire (IPAQ)

    Time frame: at baseline and Week 13.

  4. Scores on the Exercise Benefits/Barriers Scale (EBBS)

    The scale consists of two subscales: the Exercise Benefits Subscale (29 items) and the Exercise Barriers Subscale (14 items). The total score ranges from 43 to 172, with a higher score indicating a more positive perception towards exercise.

    Time frame: at baseline and Week 13

  5. Change in Knee Extension Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during knee extension

    Time frame: at baseline, Week 8, and Week 13.

  6. Change in Knee Extension Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal knee extension contractions.

    Time frame: at baseline, Week 8, and Week 13.

  7. Change in Knee Extension Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13.

  8. Change in Knee Extension Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13.

  9. Change in Knee Flexion Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during Knee Flexion measured at a preset angular velocity

    Time frame: at baseline, Week 8, and Week 13

  10. Change in Knee Flexion Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal Knee Flexion contractions

    Time frame: at baseline, Week 8, and Week 13

  11. Change in Knee Flexion Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  12. Change in Knee Flexion Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  13. Change in Shoulder Flexion Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during Shoulder Flexion, measured at a preset angular velocity.

    Time frame: at baseline, Week 8, and Week 13

  14. Change in Shoulder Flexion Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal Shoulder Flexion contractions

    Time frame: at baseline, Week 8, and Week 13

  15. Change in Shoulder Flexion Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  16. Change in Shoulder Flexion Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  17. Change in Shoulder Abduction Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during Shoulder Abduction , measured at a preset angular velocity

    Time frame: at baseline, Week 8, and Week 13

  18. Change in Shoulder Abduction Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal Shoulder Abduction contractions

    Time frame: at baseline, Week 8, and Week 13

  19. Change in Shoulder Abduction Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  20. Change in Shoulder Abduction Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  21. Change in Elbow Extension Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during Elbow Extension, measured at a preset angular velocity

    Time frame: at baseline, Week 8, and Week 13

  22. Change in Elbow Extension Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal Elbow Extension contractions

    Time frame: at baseline, Week 8, and Week 13

  23. Change in Elbow Extension Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  24. Change in Elbow Extension Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  25. Change in Elbow Flexion Peak Torque assessed by Isokinetic Dynamometry

    Maximum torque generated during Elbow Flexion, measured at a preset angular velocity

    Time frame: at baseline, Week 8, and Week 13

  26. Change in Elbow Flexion Total Work assessed by Isokinetic Dynamometry

    Total work performed during repeated maximal Elbow Flexion contractions

    Time frame: at baseline, Week 8, and Week 13

  27. Change in Elbow Flexion Average Power assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  28. Change in Elbow Flexion Fatigue Index assessed by Isokinetic Dynamometry

    Time frame: at baseline, Week 8, and Week 13

  29. Change in Rhythmic Weight Shift (RWS) Score assessed by Computerized Dynamic Posturography

    Measured using a computerized dynamic posturography system.

    Time frame: at baseline, Week 8, and Week 13.

  30. Change in Modified Clinical Test of Sensory Interaction on Balance (mCTSIB) Score assessed by Computerized Dynamic Posturography

    Measured using a computerized dynamic posturography system.

    Time frame: at baseline, Week 8, and Week 13.

  31. Change in Sensory Organization Test (SOT) Composite Score assessed by Computerized Dynamic Posturography

    Measured using a computerized dynamic posturography system.

    Time frame: at baseline, Week 8, and Week 13.

  32. Change in Motor Control Test (MCT) Latency assessed by Computerized Dynamic Posturography

    Measured using a computerized dynamic posturography system.

    Time frame: at baseline, Week 8, and Week 13.

  33. Change in Limits of Stability (LOS) Score assessed by Computerized Dynamic Posturography

    Measured using a computerized dynamic posturography system.

    Time frame: at baseline, Week 8, and Week 13.

  34. Change in Muscle Mass assessed by Bioelectrical Impedance Analysis

    Time frame: at baseline and Week 13.

  35. Change in Body Fat Percentage assessed by Bioelectrical Impedance Analysis

    Time frame: at baseline and Week 13.

  36. Change in Fat-Free Mass assessed by Bioelectrical Impedance Analysis

    Time frame: at baseline and Week 13.

  37. Change in Waist-to-Hip Ratio

    Ratio of waist circumference to hip circumference

    Time frame: at baseline and Week 13.

  38. Change in Center of Mass Sway Amplitude during Baduanjin Exercise assessed by 3D Motion Capture

    Magnitude of anteroposterior and mediolateral displacement of the body's center of mass during static postures of Baduanjin, analyzed using a markerless 3D motion capture system

    Time frame: at baseline and Week 13

  39. Change in Joint Range of Motion during Baduanjin Exercise assessed by 3D Motion Capture

    Angular displacement of primary joints during the performance of Baduanjin movements, analyzed using a markerless 3D motion capture system.

    Time frame: at baseline and Week 13

  40. Change in Center of Mass Height during Baduanjin Exercise assessed by 3D Motion Capture

    Time frame: at baseline and Week 13

  41. Change in Integrated Electromyography (iEMG) during Baduanjin Exercise assessed by Surface Electromyography

    Time frame: at baseline and Week 13

  42. Change in Root Mean Square (RMS) Amplitude during Baduanjin Exercise assessed by Surface Electromyography

    Time frame: at baseline and Week 13

  43. Change in Glycemic Control Biomarkers

    Fasting venous blood samples will be analyzed for indicators of glucose metabolism, such as glycated hemoglobin (HbA1c) and fasting insulin.

    Time frame: at baseline and Week 13.

  44. Change in Lipid Profile

    Fasting venous blood samples will be analyzed for indicators of lipid metabolism, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).

    Time frame: at baseline and Week 13.

  45. Change in Inflammatory and Neurotrophic Biomarkers

    Fasting venous blood samples will be analyzed for inflammatory markers (e.g., high-sensitivity C-reactive protein \[hs-CRP\], interleukin-6 \[IL-6\], tumor necrosis factor-alpha \[TNF-α\]) and brain-derived neurotrophic factor (BDNF).

    Time frame: at baseline and Week 13.

  46. Percentage of Prescribed Baduanjin Sessions Completed

    Time frame: Through study completion, up to Week 13.

  47. Baduanjin Movement Quality Score assessed by Blinded Expert Review (100-point scale)

    Score assessed by blinded experts using a standardized 100-point scoring rubric. Scores range from 0 to 100, with a higher score indicating better movement quality.

    Time frame: at Week 13

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Apr 2026 → Sep 2026, primary completion Jul 2027 → Sep 2027 and completion Aug 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 19, 2026
StartActual
Sep 30, 2026was Apr 2026
Primary completionEst.
Sep 30, 2027was Jul 2027
CompletionEst.
Oct 10, 2027was Aug 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in China
Show site
  • China-Japan Friendship Hospital · Beijing, China
Nov 5, 2026
Start date
Apr 10, 2026→Sep 30, 2026 (actual)
Nov 5, 2026
Primary completion
Jul 10, 2027→Sep 30, 2027
Nov 5, 2026
Study completion
Aug 10, 2027→Oct 10, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • China-Japan Friendship Hospital · Beijing, China
    Start date Apr 10, 2026→Sep 30, 2026 (now actual)
    Primary completion Jul 10, 2027→Sep 30, 2027
    Study completion Aug 10, 2027→Oct 10, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07482995
Responsible party
Jingyi Ren (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
Mar 19, 2026
Start date
Sep 30, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 10, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Jingyi Ren, M.D., Chief Physician
Contact
renjingyi@cjfh.org.cn
18600195099

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion